^
    Back
    Association details:
    Biomarker:BRCA2 mutation + HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    For those with germline BRCA1/2 mutations and HR-positive, HER2-negative disease who received preoperative chemotherapy, consider adjuvant olaparib…
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Medicine (Baltimore)
    Title:

    Clinical relevance of receptor conversion in metastatic breast cancer: Case report

    Published date:
    06/10/2022
    Excerpt:
    A 40-year-old Caucasian woman with germline breast cancer gene mutation was referred to a general surgery...Genetic testing revealed the presence of BRAC2 germline mutations....Ultrasound-guided microbiopsy revealed an invasive ductal carcinoma of no special type, hormone receptor-positive, and HER2-negative....After full approval from the regulatory entities, the patient was administered olaparib (300 mg) twice daily in July/2021. After seven cycles of olaparib 300 mg twice daily, the patient remained stable without any significant adverse events.
    DOI:
    10.1097/MD.0000000000029136